CClinicalTrials.gg
CompletedNCT05319327METHYL-UPUpdated Oct 9, 2024

Targeting DNA-methylation Fingerprints Linked to Ultra-Processed Foods Consumption to Prevent Non-communicable Diseases: the METHYL-UP Study

An interventional study of Nutritional intervention and Control in Obesity and Overweight, sponsored by IMDEA Food. Completed at 1 site in Spain. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2024-10-09.

Sponsored by IMDEA Food · Not applicable, Interventional, and Prevention

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Jun 2021, registered Mar 2022).
Phase
Not applicable
Study type
Interventional
Enrollment
33
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

Non-communicable diseases (NCD) are the main health challenge in industrialized countries. However, these diseases are preventable if an intervention based on lifestyle is implemented at the population level. Diet has a great impact on the onset and progression of NCD. In this regard, ultra-processed food (UPF) consumption has been related to higher morbidity and mortality. UPF are defined as "formulations made mostly or entirely from substances derived from foods and additives, with little if any intact unprocessed or minimally processed foods" (NOVA definition). UPF are rich in saturated fats and additives and poor in fiber other nutrients. UPF consumption has raised in the last decades in the industrialized countries and this increase has been associated with higher prevalence of metabolic disorders such as diabetes, obesity, metabolic syndrome, cardiovascular disease, and cancer. However, mechanisms that link UPF consumption with NCD are poorly understood and clinical trials are needed to unravel these mechanisms and how to impact on them through lifestyle interventions. The investigators have previously identified DNA methylation marks associated with UPF consumption. DNA methylation marks are modifiable. The aim of the study is to assay if DNA methylation marks related to UPF consumption are reversible by reducing UPF consumption in a population of adults with overweight or obesity and with a high basal UPF consumption (>35% of total food consumption in g/day).

Read the detailed description

The investigators propose a controlled, randomized, parallel groups intervention study based on nutritional counseling to reduce UPF consumption. Eligible participants are adults (18-50 years old), men and women, with overweight or obesity (BMI 25-40 Kg/m2) with a high basal consumption of UPF (>35% of total intake in g/day).

Recruited participants will be randomly allocated into a control group or an intervention group. Participants in the control group will be provided with nutritional guidelines to follow a healthy diet based on a Mediterranean diet. Participants in the intervention group will follow a nutritional intervention program aimed to reduce UPF consumption. Nutritional intervention will not modify basal caloric intake but will record energy intake along the intervention. Nutritional counseling will be based on nutritional educational material such as encourage and discourage food items, recipes, menus and food shopping lists based on unprocessed or minimally processed foods.

Total intervention will last 6 months for both groups. During the intervention phase, a monthly interview with nutritionist/dietitian is scheduled. Face-to-face interviews will be carried out in months 2 and 4. Phone interviews will be carried out in months 1, 3 and 5. In the baseline and final visits (months 0 and 6) a sample and data collection will be performed.

Data collected will include general socio-demographical data (age, sex, educational level, working status, civil status, rural/urban status), lifestyle data (smoking habits, dietary habits, physical activity, sleeping habits), anthropometric data (height, weight, waist circumference, body composition), and clinic-phenotypical parameters (blood pressure, medication, adverse effects, disease prevalence). Biological sample collection will include blood, urine, saliva and feces. Biochemical and blood cells parameters will be measured (blood cell count, glucose, lipid and hepatic profiles).

02

Conditions studied

  • Obesity
  • Overweight

Keywords

  • Epigenetics
  • Methylation
  • Clinical trial
  • Causal inference
  • Non-communicable diseases
  • Precision nutrition
  • Ultra-processed food
  • NOVA
  • Obesity
03

In context

Overweight

3,670 studies on the registry are indexed under Overweight; 849 are open to participants now.

This study's enrollment of 33 is below the median of 73 across 3,175 interventional studies indexed under Overweight.

Browse Overweight studies →

Lead sponsor

IMDEA Food is the lead sponsor of 17 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Men/women
  • 18-50 years old
  • BMI 25-40 Kg/m2
  • UPF consumption > 35% of total intake in g/day

Exclusion criteria

Exclusion Criteria:

  • Pregnancy
  • Menopause
  • IMC \<25 Kg/m2 or > 40 Kg/m2
  • Excessive alcohol consumption
  • Prevalent cardiovascular, renal, lung, pancreatic or liver disease
  • Type 1 diabetes
  • Type 2 diabetes with poor glucose control or unstable medication during last 3 months
  • Prevalent endocrine disease
  • Changes in anti-hypertensive medication during last 3 months
  • Insulin, systemic anti-inflammatory, or glucocorticoid medication during last 3 months
  • Food allergies or intolerances
  • Psychosocial or cultural factors that prevent from following the intervention
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
33 participants (actual)

Study arms

  • Active comparator
    Control Group

    Participants in the control group will be provided with nutritional guidelines to follow a healthy diet based on a Mediterranean diet.

    Other: Control

  • Experimental
    Intervention group

    Participants in the intervention group will follow a nutritional intervention program aimed to reduce UPF consumption. Nutritional intervention will not modify basal caloric intake but will record energy intake along the intervention. Nutritional counseling will be based on nutritional educational material such as encouraged and discouraged food items, recipes, menus and food shopping lists based on unprocessed or minimally processed foods.

    Other: Nutritional intervention

Interventions

  • OtherNutritional intervention

    A nutritional intervention program aimed to reduce UPF consumption. Nutritional intervention will not modify basal caloric intake but will record energy intake along the intervention. Nutritional counseling will be based on nutritional educational material such as encouraged and discouraged food items, recipes, menus and food shopping lists based on unprocessed or minimally processed foods. Total intervention will last 6 months for both groups. During the intervention phase, a monthly interview with nutritionist/dietitian is scheduled. Face-to-face interviews will be carried out in months 2 and 4. Phone interviews will be carried out in months 1, 3 and 5. In the baseline and final visits (months 0 and 6) a sample and data collection will be performed.

    Also known as: Reduction of UPF consumption

  • OtherControl

    General counseling to adhere to a healthy Mediterranean diet

06

What researchers measure

Primary outcomes

  1. UPF

    Ultra-processed food consumption

    Time frame: 6 months

Secondary outcomes

  1. Weight

    Weight change (Kg)

    Time frame: 6 months

  2. BMI

    Change in body mass index (Kg/m2)

    Time frame: 6 months

  3. Obesity

    Percentage of participants who reverse obesity condition (BMI \< 30 Kg/m2)

    Time frame: 6 months

  4. Body composition

    Change in % of fat mass

    Time frame: 6 months

Other outcomes

  1. DNA methylation

    Reversibility of DNA methylation marks

    Time frame: 12 months

  2. Glucose

    Change in fastin glucose levels (mg/dL)

    Time frame: 9 months

  3. Glycated haemoglobin

    Change in fastin glycated haemoglobin levels (%)

    Time frame: 9 months

  4. Triglycerides

    Change in fasting triglycerides levels (mg/dL)

    Time frame: 9 months

  5. LDL-cholesterol

    Change in fasting LDL-cholesterol levels (mg/dL)

    Time frame: 9 months

  6. HDL-cholesterol

    Change in fasting HDL-cholesterol levels (mg/dL)

    Time frame: 9 months

  7. Liver profile

    Change in HSI liver function index

    Time frame: 9 months

  8. Microbiota

    Changein microbiota diversity

    Time frame: 24 months

07

Study locations

1 site
  • IMDEA Food
    Madrid, 28049, Spain
08

References and documents

Individual participant data

Plan to share: No — Informed consent does not allow to make data publicly available. Nevertheless, data could be share upon request to the investigators.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Oct 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05319327
Lead sponsor
IMDEA Food
Responsible party
Lidia Daimiel Ruiz (Senior Researcher, IMDEA Food) — Principal investigator
First posted
Apr 8, 2022
Start date
Jun 6, 2021
Primary completion
Dec 31, 2022
Completion
Dec 31, 2022
Last update
Oct 9, 2024

Study contacts

José M Ordovás, PhD
study director · Fundación IMDEA Alimentación

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion